Access to Patient-Level Data from GlaxoSmithKline Clinical Trials
Open accessThe DOI matches its Crossref record.
Abstract
Efforts are under way to increase the transparency of clinical trial data.Among the efforts are those being undertaken at GlaxoSmithKline, where we have recently made a commitment to provide access to deidentified patient-level data.We are taking this step because it is the right thing to do, both scientifically and for society, and it is in line with our company's commitment to transparency in clinical trial reporting.As of May 2013, investigators are able to request access to deidentified patient-level data from a subset of GlaxoSmithKline-sponsored clinical trials.We expect that research teams requesting data will have sufficient statistical and data-management expertise to evaluate these data sets, and we call for standards in analysis to be defined by the scientific community.This article describes the approach we are adopting and answers some of the most common questions we have received since our announcement of this policy.Which GlaxoSmithKline studies will be available?The GlaxoSmithKline Clinical Study Requests website (https://clinicalstudydata.gsk.com)lists studies available as of May 7, 2013, when the website was launched.These studies are also listed in Section 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.The list includes clinical studies of medicines that have been approved for specific indications (anywhere in the world) and medicines that have been terminated from development.Manuscripts describing the results of a study -whether they are perceived as positive or negative -are submitted for publication within 18 to 24 months after the last study visit by the last participant enrolled.A study is added to the list once the primary manuscript describing the results has been accepted for publication.Studies that have not been accepted for publication, as well as those that are not submitted or are no longer being submitted for publication, are also available.1.Data Protection Working Party.Opinion 4/2007 on the concept of personal data (http://ec.europa.eu/justice/policies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
The legal and ethical concerns that arise from using complex predictive analytics in health care
Cohen, I. G., Amarasingham, R., Shah, A., Xie, B., & Lo, B. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0048 · Cited by 300
Preparing for Responsible Sharing of Clinical Trial Data
Mello, M. M., Francer, J. K., Wilenzick, M., Teden, P., Bierer, B. E., & Barnes, M. (2013) · New England Journal of Medicine · doi:10.1056/nejmhle1309073 · Cited by 175
Danchev, V., Min, Y., Borghi, J., Baiocchi, M., & Ioannidis, J. P. A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33972 · Cited by 94
Rockhold, F., Nisen, P., & Freeman, A. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1608086 · Cited by 55
Self-citation
Metadata
- Authors
- Nisen, P., & Rockhold, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08
- Volume
- 369
- Issue
- 5
- Pages
- 475-478
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2076925836
- Cited by
- 120
- References
- 0
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. https://app.cochat.ai/papers/10.1056/nejmsr1302541
- The paper
- Nisen, P., & Rockhold, F. (2013). Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. New England Journal of Medicine. https://doi.org/10.1056/nejmsr1302541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.